Editas Medicine
Linda Burkly is an experienced biotechnology executive currently serving as Executive Vice President and Chief Scientific Officer at Editas Medicine since July 2023. Before this role, Linda held positions as a Strategic Advisor at Exo Therapeutics, Inc. and as an Advisor at Lightstone Ventures Capital Management, LLC. Linda's expertise includes providing strategic and scientific advice on novel therapeutic development in immunology and neurology through Linda C Burkly, LLC. From 1985 to 2022, Linda was a Vice President and Senior Distinguished Investigator at Biogen, where significant contributions were made to genetic and neurodevelopmental disorders and acute neurology. Linda earned a Ph.D. in Immunology from Tufts University Graduate School of Biomedical Science and a Bachelor of Science in Biology from Fairfield University.
This person is not in any offices